Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 15, 2008, Pages 4433-4437

  Angell, Richard M ^a   Angell, Tony D ^a   Bamborough, Paul ^a   Bamford, Mark J ^a   Chung, Chun wa ^a   Cockerill, Stuart G ^a   Flack, Stephen S ^a   Jones, Katherine L ^a   Laine, Dramane I ^a   Longstaff, Timothy ^a   Ludbrook, Steve ^a   Pearson, Rosannah ^a   Smith, Kathryn J ^a   Smee, Penny A ^a   Somers, Don O ^a   Walker, Ann L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Binding mode; Biphenyl amide; DFG out; Kinetics; MAP kinase; p38 Kinase inhibitors; Protein kinase X ray structure; Selectivity

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DORAMAPIMOD; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ARTICLE; BINDING KINETICS; DRUG BINDING; HUMAN; HUMAN CELL; PROTEIN CONFORMATION; X RAY;

AMIDES; AMINO ACIDS; BINDING SITES; BIPHENYL COMPOUNDS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; LIPOPOLYSACCHARIDES; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NAPHTHALENES; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47749106789     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.028     Document Type: Article

References (26)

1. Angell R., Bamborough P., Cleasby A., Cockerill S., Jones K., Mooney C., Neu M., Somers D., and Walker A. Bioorg. Med. Chem. Lett. 18 (2008) 318
2. Angell R., Angell T., Bamborough P., Brown D., Brown M., Buckton J., Cockerill S., Edwards C., Jones K., Longstaff T., Smee P., Smith K., Somers D., Walker A., and Willson M. Bioorg. Med. Chem. Lett. 18 (2008) 324
3. Angell R., Aston N., Bamborough P., Buckton J., Cockerill S., deBoeck S., Edwards C., Holmes S., Jones K., Laine D., Patel S., Smee P., Somers D., and Walker A. Bioorg. Med. Chem. Lett. 18 (2008) 4428
4. Pargellis C., Tong L., Churchill L., Cirillo P., Gilmore T., Graham A., Grob P., Hickey E., Moss N., Pav S., and Regan J. Nat. Struct. Biol. 9 (2002) 268
5. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A., Hickey E., Klaus B., Madwed J., Moriak M., Moss N., Pargellis C., Pav S., Proto A., Swinamer A., Tong L., and Torcellini C. J. Med. Chem. 45 (2002) 2994
6. Regan J., Capolino A., Cirillo P., Gilmore T., Graham A., Hickey E., Kroe R., Madwed J., Moriak M., Nelson R., Pargellis C., Swinamer A., Torcellini C., Tsang M., and Moss N. J. Med. Chem. 46 (2003) 4676
7. Regan J., Pargellis C., Cirillo P., Gilmore T., Hickey E., Peet G., Proto A., Swinamer A., and Moss N. Bioorg. Med. Chem. Lett. 13 (2003) 3101
8. Sullivan J., Holdgate G., Campbell D., Timms D., Gerhardt S., Breed J., Breeze A., Bermingham A., Pauptit R., Norman R., Embrey K., Read J., VanScyoc W., and Ward W. Biochemistry 44 (2005) 16475
9. Dumas J., Smith R., and Lowinger T. Curr. Opin. Drug Disc. Devel. 7 (2004) 600
10. Gill A., Frederickson M., Cleasby A., Woodhead S., Carr M., Woodhead A., Walker M., Congreve S., Devine L., Tisi D., O'Reilly M., Seavers L., Davis D., Curry J., Anthony R., Padova A., Murray C., Carr R., and Jhoti H. J. Med. Chem. 48 (2005) 414
11. Schindler T., Bornmann W., Pellicena P., Miller W., Clarkson B., and Kuriyan J. Science 289 (2000) 1938
12. W)*1000, as defined by. Abad-Zapatero C., and Metz J. Drug Discovery Today 10 (2005) 464
13. Compounds given in Table 2 are representative of an array prepared from substituted benzoic acids as shown in Scheme 2 of Ref. 3, using several amide coupling conditions. Compounds given in Table 3 were prepared as shown in Scheme 1 of Ref. 3, also using a number of different amide coupling conditions. For 22-24, cyclopropylmethyl-amine in step a was replaced with 3-aminobenzonitrile.
14. 1,3 X-ray diffraction data were collected from the crystal at 100 K (using an Oxford Cryostream) at Daresbury Laboratory SRS (station 9.6) using an ADSC Q4R CCD detector. The data were processed with the HKL package (Otwinowski, Z.; Minor, W. Methods Enzymol. 1997, 276:Macromol. Crystallogr. A, 307) and CCP4 program suite (Bailey, S. Acta Crystallogr., 1994, D50, 760). The structure was solved using the native p38 coordinates (PDB entry 1WFC) as the initial model in refinement by REFMAC (Murshudov, G.; Vagin, A.; Dodson, E. Acta Crystallogr. 1997, D53, 240). The final R-factor achieved for the complex was 17.5%. Coordinates have been deposited in the PDB as entry 3D83. Figures were produced using Pymol (DeLano, W. L. DeLano Scientific, Palo Alto, CA, USA. http://www.pymol.org).
15. Inhibition of phosphorylation of ATF-2 by activated p38α was measured as described in Ref. 3.
16. Experiments were performed at 25 °C on a BIAcore S51 instrument. Human unphosphorylated p38α (as used in the crystallography) was immobilised using random amine coupling onto a CM5 chip in the presence of SB-203580 at pH 5.3 in 50 mM NaAc at normally 3-4kRU. Compounds were titrated over p38α in 50 mM Hepes pH 7.4, 150 mM NaCl, 1% DMSO, typically in doubling or tripling dilutions from 3.7 μM. BIAcore software and Grafit were used to extract on- and off-rates to ensure consistency and reproducibility.
17. Kroe R., Regan J., Proto A., Peet G., Roy T., Landro L., Fuschetto N., Pargellis C., and Ingraham R. J. Med. Chem. 46 (2003) 4669
18. Lipinski C., Lombardo F., Dominy B., and Feeney P. Adv. Drug Deliv. Rev. 23 (1997) 3
19. Okram B., Nagle A., Adrian F., Lee C., Ren P., Wang X., Sim T., Xie Y., Wang X., Xia G., Spraggon G., Warmuth M., Liu Y., and Gray N. Chem. Biol. 13 (2006) 779
20. Young P., McLaughlin M., Kumar S., Kassis S., Doyle M., McNulty D., Gallagher T., Fisher S., McDonnell P., Carr S., Huddleston M., Seibel G., Porter T., Livi J., Adams J., and Lee J. J. Biol. Chem. 272 (1997) 12116
21. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keefe S.J., and O'Neill E.A. Biochemistry 37 (1998) 13846
22. Kuma Y., Sabio G., Bain J., Shpiro N., Marquez R., and Cuenda A. J. Biol. Chem. 280 (2005) 19472
23. Ross S., Chen T., Yu V., Tudor Y., Zhang D., Liu L., Tamayo N., Dominguez C., and Powers D. Assay Drug Dev. Technol. 4 (2006) 397
24. 50 > 10 μM 7 times and <250 nM 9 times.
25. Adams J., Boehm J., Gallagher T., Kassis S., Webb E., Hall R., Sorenson M., Garigipati R., Griswold D., and Lee J. Bioorg. Med. Chem. Lett. 11 (2001) 2867
26. KinomeScan assays were carried out at Ambit Biosciences and interpreted as described in Ref. 3. Data for BIRB-796 are taken from. Fabian M., et al. Nat. Biotechnol. 23 (2005) 329